Invention Grant
- Patent Title: Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
-
Application No.: US16629585Application Date: 2018-07-09
-
Publication No.: US11447545B2Publication Date: 2022-09-20
- Inventor: Stéphanie Cornen , Benjamin Rossi , Nicolai Wagtmann
- Applicant: INNATE PHARMA
- Applicant Address: FR Marseilles
- Assignee: INNATE PHARMA
- Current Assignee: INNATE PHARMA
- Current Assignee Address: FR Marseilles
- Agency: Saliwanchik, Lloyd & Eisenschenk
- International Application: PCT/EP2018/068532 WO 20180709
- International Announcement: WO2019/011852 WO 20190117
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61P35/00 ; A61K39/00
Abstract:
This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.
Public/Granted literature
- US20200369764A1 COMBINATION THERAPY USING ANTIBODY TO HUMAN SIGLEC-9 AND ANTIBODY TO HUMAN NKG2A FOR TREATING CANCER Public/Granted day:2020-11-26
Information query
